cst-1 Antibody
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
Here’s a structured FAQ collection for CST1 antibody research, organized by basic and advanced inquiries, grounded in academic rigor and methodological detail:
How do I validate the specificity of CST1 antibodies in immunohistochemistry (IHC)?
Methodological Answer:
-
Antibody Validation: Use knockout cell lines or tissues (e.g., CRISPR-edited CST1-deficient models) as negative controls .
-
Cross-Reactivity Testing: Perform Western blot (WB) against related cystatins (CST2, CST4) to confirm no off-target binding .
-
Blocking Peptide Assays: Pre-incubate the antibody with CST1 recombinant protein (e.g., Ag9068) to verify signal loss .
Table 1: CST1 Antibody Validation Data
| Assay Type | Target Specificity | Cross-Reactivity Tested | Reference |
|---|---|---|---|
| WB | 16 kDa band | CST2, CST4 (no binding) | |
| IHC | Cytoplasmic | Knockout tissue (negative) |
What are the optimal applications for CST1 antibodies in cancer research?
Methodological Answer:
-
Early Cancer Detection: Use ELISA to quantify serum CST1 levels. NSCLC patients show elevated CST1 (4,289 ± 2,405 pg/mL vs. 1,558 pg/mL in benign nodules) .
-
Functional Studies: Pair WB with migration/invasion assays (e.g., Transwell) to link CST1 expression to metastasis .
-
Multi-Marker Panels: Combine CST1 with Cyfra21-1 and CEA for NSCLC diagnostics (AUC = 0.914) .
How to resolve contradictory CST1 expression data across cancer types?
Methodological Answer:
-
Tissue-Specific Analysis: Validate findings using organoid models or patient-derived xenografts to account for tumor microenvironment variations .
-
Post-Translational Modifications: Perform deglycosylation assays (e.g., PNGase F treatment) to assess if glycosylation affects antibody binding .
-
Multi-Omics Integration: Correlate CST1 mRNA (TCGA data) with protein levels (IHC/WB) to identify regulatory discrepancies .
Table 2: CST1 Expression in Cancer
| Cancer Type | Expression Trend | Functional Role | Key Pathway |
|---|---|---|---|
| NSCLC | Upregulated | Diagnostic marker | EGFR/MEK/ERK |
| Breast | Upregulated | Metastasis driver | OXPHOS/MEK/ERK |
| Esophageal | Upregulated | Promotes invasion | GRIM19 complex I |
What strategies improve CST1 detection in low-abundance biological fluids?
Methodological Answer:
-
Pre-Analytical Enrichment: Use immunoprecipitation (IP) with biotinylated antibodies (e.g., MAB1285-SP) to concentrate CST1 from saliva or serum .
-
High-Sensitivity ELISA: Optimize antibody pairs (polyclonal capture + monoclonal detection) with a lower limit of detection (<50 pg/mL) .
-
Mass Spectrometry Backup: Employ targeted proteomics (e.g., PRM) to cross-validate ELISA results .
How to design functional studies for CST1 in tumor progression?
Methodological Answer:
-
Genetic Manipulation: Use siRNA/shRNA knockdown in cell lines (e.g., A549, MCF-7) to assess proliferation/apoptosis .
-
In Vivo Models: Inject CST1-overexpressing cells into nude mice and monitor metastasis via bioluminescence .
-
Pathway Inhibition: Treat cells with MEK/ERK inhibitors (e.g., PD98059) to dissect CST1’s role in signaling cascades .
Key Data Contradictions & Resolutions
-
Contradiction: CST1 shows variable prognostic value (favorable in NSCLC , unfavorable in breast cancer ).
Resolution: Context-dependent roles—analyze co-expression networks (e.g., CST1 + GPX4 in ferroptosis ). -
Contradiction: Inconsistent WB band sizes (14–16 kDa vs. 16 kDa ).
Resolution: Use reducing gels and validate with recombinant CST1 controls .
